Department of Medical Oncology, Clatterbridge Centre for Oncology, Merseyside, United Kingdom.
PLoS One. 2010 Jan 28;5(1):e8933. doi: 10.1371/journal.pone.0008933.
The majority of chemotherapy drugs are dosed based on body surface area (BSA). No standard BSA values for patients being treated in the United Kingdom are available on which to base dose and cost calculations. We therefore retrospectively assessed the BSA of patients receiving chemotherapy treatment at three oncology centres in the UK between 1(st) January 2005 and 31(st) December 2005.A total of 3613 patients receiving chemotherapy for head and neck, ovarian, lung, upper GI/pancreas, breast or colorectal cancers were included. The overall mean BSA was 1.79 m(2) (95% CI 1.78-1.80) with a mean BSA for men of 1.91 m(2) (1.90-1.92) and 1.71 m(2) (1.70-1.72) for women. Results were consistent across the three centres. No significant differences were noted between treatment in the adjuvant or palliative setting in patients with breast or colorectal cancer. However, statistically significant, albeit small, differences were detected between some tumour groups.In view of the consistency of results between three geographically distinct UK cancer centres, we believe the results of this study may be generalised and used in future costings and budgeting for new chemotherapy agents in the UK.
大多数化疗药物的剂量是根据体表面积(BSA)来确定的。在英国,没有可供治疗患者的标准 BSA 值来进行剂量和成本计算。因此,我们回顾性评估了 2005 年 1 月 1 日至 12 月 31 日期间在英国三家肿瘤中心接受化疗治疗的患者的 BSA。共有 3613 名接受头颈部、卵巢、肺癌、上胃肠道/胰腺、乳腺癌或结直肠癌化疗的患者被纳入研究。总体平均 BSA 为 1.79 m²(95%CI 1.78-1.80),男性平均 BSA 为 1.91 m²(1.90-1.92),女性为 1.71 m²(1.70-1.72)。三个中心的结果一致。在乳腺癌或结直肠癌患者的辅助治疗或姑息治疗中,治疗之间没有明显差异。然而,在一些肿瘤组之间检测到了统计学上显著的(尽管很小)差异。鉴于三个地理位置不同的英国癌症中心之间的结果具有一致性,我们认为本研究的结果可能具有普遍性,并可用于未来英国新化疗药物的成本核算和预算编制。